Current Trials
ECHO Open to Accrual Clinical Trials
Updated: 05/2/2025
| Colorectal Metastatic (Janssen) Origami 61186372COR3002 A randomized, Open-label Phase 3 study of Amivantamab + Folfiri Versus Cetuximab/Bevacizumab + Folfiri in participants with KRAS/NRAS and BRAF wild-type recurrent, Unresectable or Metastatic Colorectal Cancer who have received prior chemotherapy WO42758 / INTRINSIC A Phase I/Ib Global, Multicenter, Open-Label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC) Lung First Line Metastatic: Amgen AMG 193 20230153 A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Mirati 849-007 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation OSE210C302 (Artemia) A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to immune checkpoint inhibitor (ICI)-Artemia study Lymphoma MK-1026-011 (BELL WAVE-011)A Phase 3, Randomized Study to Compare Nemtabrutinib versus comparator (Investigator’s choice of Ibrutinib or Acalabrutinib) in participants with untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Solid Tumors AMG 193 20230167 A Phase 1b Study Evaluating the safety, tolerability, Pharmacokinetics, and efficacy of AMG 193 alone or in combination with other therapies in subjects with Advanced Thoracic Tumors with Homozygous MTAP-deletion AMG 20230246 A Non-Interventional Biomarker Study on the molecular evaluation of Archival Tumor Tissue in subjects with advanced or metastatic malignancies Supportive Care LP-CT-PALO-202101 A randomized, Double-Blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy TP-CA-002 Tempus Gemini NSCLC Surveillance Study A longitudinal multiomic biomarker profiling study of patients with Non-Small Cell Lung Cancer (NSCLC) TP-CA-007 Tempus Aries A Biobank Registry Platform Study in Oncology |
For more information on clinical trials, please contact Dr. Susan Johnson, Director of Research sjohnson@echoct.com or 860-886-8362.
To learn about phases of trials and what it means to participate, click here.